Managing anemia in lymphoma and multiple myeloma

Therapeutics and Clinical Risk Management

Volumn 4, Issue 2, 2008, Pages 527-539

  Birgegård, Gunnar ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer anemia; Epo; Epoetin; ESA; Lymphoma; Lymphoproliferative disease; Myeloma

Indexed keywords

ANTIANEMIC AGENT; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; ERYTHROPOIESIS STIMULATING AGENT; ERYTHROPOIETIN; FERRIC FERROCYANIDE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROPORTIN; FERROUS SULFATE; HEPCIDIN; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR; VINCRISTINE;

ANEMIA; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; EARLY INTERVENTION; ERYTHROCYTE LIFESPAN; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY; FUNCTIONAL IRON DEFICIENCY; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; IRON DEFICIENCY; IRON METABOLISM; IRON THERAPY; KIDNEY DYSFUNCTION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MULTIPLE MYELOMA; NUTRITIONAL DEFICIENCY; OXYGEN DISSOCIATION CURVE; PURE RED CELL ANEMIA; QUALITY OF LIFE; REVIEW; TUMOR GROWTH; VISUAL ANALOG SCALE;

EID: 44049088602     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Auerbach M, Ballard H, Trout JR, et al. 2004. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol, 22:1301-7.
2. Barrett-Lee PJ, Ludwig H, Birgegård G, et al. 2006. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anemia Survey. Oncology, 70:34-48.
3. Beguin Y. 1998. Prediction of response to treatment with recombinant human erythropoietin in anemia associated with cancer. Med Oncol, 15(Suppl 1):S38-46.
4. Birgegård G, Aapro MS, Bokemeyer C, et al. 2005. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology, 68(Suppl 1):3-11.
5. Birgegård G, Gascón P, Ludwig H. 2006. Evaluation of anemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anemia Survey. Eur J Haematol, 77:378-86.
6. Birgegård G, Dahl F, Glimelius B, et al. 2007. Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment. Med Oncol, 24:318-22.
7. Bohlius J, Wilson J, Seidenfeld J, et al. 2006a. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst, 98:708-14.
8. Bohlius J, Weingart O, Trelle S, et al. 2006b. Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nat Clin Pract Oncol, 3:152-64.
9. Bokemeyer C, Aapro MS, Courdi A, et al. 2004. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer, 40:2201-16.
10. Bokemeyer C, Aapro MS, Courdi A, et al. European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. 2007. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer, 43:258-70.
11. Casadevall N, Nataf J, Viron B, et al. 2002. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Eng J Med, 346:469-75.
12. Cavill I, Auerbach M, Bailie GR, et al. 2006. Iron and the anemia of chronic disease. Curr Med Res Opin, 22:731-37.
13. Cazzola M, Ponchio L, Pedrotti C, et al. 1996. Prediction of response to recombinant human erythropoietin in anemia of malignancy. Hematologica, 81:434-41.
14. Cella D. 1997. The Functional Assessment of Cancer-Therapy Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol, 34:13-19.
15. Cella D. 2002. The effects of anemia and anemia treatment on the quality of life of people with cancer. Oncology (Williston Park), 16(9 Suppl 10):125-32.
16. Cella D, Dobrez O, Glaspy J. 2003a. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol, 14:511-19.
17. Cella D, Zagari MJ, Vandoros C, et al. 2003b. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol, 21:366-73.
18. Coiffier B, Guastalla JP, Pujade-Lauraine E, et al. Anemia Study Group. 2001. Predicting cancer-associated anemia in patients receiving non-platinum chemotherapy. Eur J Cancer, 37:1617-23.
19. Crawford J, Cella D, Cleeland CS, et al. 2002. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer, 95:888-95.
20. Dammacco F, Castoldi G, Rödjer S. 2001. Efficacy of epoetin alfa in the treatment of anemia of multiple myeloma. Br J Haematol, 113:172-9.
21. Demetri GD, Kris M, Wade J, et al. 1998. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol, 16:3412-25.
22. Djulbegovic B. 2005. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines. Best Pract Res Clin Haematol, 18:455-66.
23. Elliott S, Busse L, Bass MB. 2006. Anti-Epo receptor anitbodies do not predict Epo receptor expression. Blood, 107:1892-5.
24. Fallowfield L, Gagnon D, Zagari M, et al. for the Epoetin Alfa Study Group. 2002. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer, 87:1341-53.
25. Faquin WC, Schneider TJ, Goldberg MA. 1992. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood, 79:1987-94.
26. Fishbane S, Frei GL, Maesaka J. 1995. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis, 26:41-6.
27. Fishbane S, Galgano S, Langley RC Jr, et al. 1997. Reticulocyte hemoglobin content in the evaluation or iron status of hemodialysis patients. Kidney Int, 52:217-22.
28. Franck S, Linssen J, Messinger M, et al. 2004. Potential utility of Ret-Y in the diagnosis of iron restricted erythropoiesis. Clin Chem, 50:1240-2.
29. Gabrilove JL, Cleeland CS, Livingston RB, et al. 2001. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol, 19:2875-82.
30. Glaspy J, Bukowski R, Steinberg D, et al. 1997. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol, 15:1218-34.
31. Groopman JE, Itri LM. 1999. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst, 91:1616-34.
32. Hagberg A, Barbany G, Landegren U, et al. 2003. Beta-globin mRNA increases rapidly during erythropoietin treatment. Scand J Clin Lab Invest, 63:239-45.
33. Hedenus M, Adriansson M, Miguel JS, et al. 2003. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol, 122:394-403.
34. Hedenus M, Birgegård O, Näsman P, et al. 2007. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia, 21:627-32.
35. Henke M, Laszig R, Rübe C, et al. 2003. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet, 362(9392):1255-60.
36. Henry D, Abels R, Larholt K. 1995. Prediction of response to recombinant human erythropoietin (r-HuEPO/epoetin-alpha) therapy in cancer patients. Blood, 85:1676-78.
37. Henry DH, Dahl NV, Auerbach M, et al. 2007. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist, 12:231-42.
38. Hesketh PJ, Arena F, Patel D, et al. 2004. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have non-myeloid malignancies. Cancer, 100:859-68.
39. Katodritou E, Speletas M, et al. 2004. Prediction of response of anemia to recombinant human erythropoietin in patients with multiple my eloma and lymphoma. Hematol J, 5(suppl 2):191.
40. Katodritou E, Terpos E, Zervas K, et al. 2007. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol, 86:369-76.
41. Kyle RA. 1975. Multiple myeloma: review of 869 cases. Mayo Clin Proc, 50:29-40.
42. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. 2005. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol, 23:5960-72.
43. Littlewood TJ, Bajetta E, Nortier JW, et al.; Epoetin Alfa Study Group. 2001. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol, 19:2865-74.
44. Ludwig H, Strasser K. 2001. Symptomatology of anemia. Semin Oncol, 28(2 Suppl 8):7-14.
45. Ludwig H, Van Belle S, Barrett-Lee P, et al. 2004. The European Cancer Anemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patients. Eur J Cancer, 40:2293-306.
46. Lyman GH, Glaspy J. 2006. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer, 106:223-33.
47. Macdougall IC, Tucker B, Thompson J, et al. 1996. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int, 50:1694-99.
48. Macdougall I. 1998. Merits of percentage of hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transplant, 13:847-49.
49. Mercadente S, Gebbia V, Marrazzo A, et al. 2000. Anemia in cancer: pathophysiology and treatment. Cancer Treat Rev, 25:303-11.
50. Miller CB, Jones RJ, Piantadosi S, et al. 1990. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med, 322:1689-92.
51. Mittelman M, Zeidman A, Fradin Z, et al. 1997. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol, 98:204-10.
52. Mittelman M, Neumann D, Peled A, et al. 2001. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA, 98:5181-6.
53. Mittelman M, Zeidman A, Kanter P, et al. 2004. Erythropoietin has an antimyeloma effect - a hypothesis based on a clinical observation supported by animal studies. Eur J Haematol, 72:155-65.
54. Moullet I, Salles G, Ketterer N, et al. 1998. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol, 9:1109-15.
55. Nowrousian MR (Ed). 2002. Pathophysiology of cancer-related anemia. Recombinant human erythropoietin in clinical oncology. New York, Springer Medicine.
56. Nemeth E, Ganz T. 2006. Regulation of iron metabolism by hepcidin. Ann Rev Nutr, 26:323-42.
57. Osterborg A, Brandberg Y, Molostova V, et al. for the Epoetin Beta Hematology Study Group. 2002. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol, 20(10):2486-94.
58. Osterborg A, Brandberg Y, Hedenus M. 2005. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol, 129:206-9.
59. Pangalis GA, Siakantaris M, Angelpolou MK, et al. 2002. Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. Hematologica, 87:500-6.
60. Punnonen K, Irjala K, Rajamaki A. 1997. Serum transferrin receptor and its ration to serum ferritin in the diagnosis of iron deficiency. Blood, 89:1052-57.
61. Quirt I, Robeson C, Lau CY, et al. 2001. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol, 19:4126-34.
62. Roy CN, Andrews NC. 2005. Anemia of inflammation: the hepcidin link. Curr Opin Haematol, 12:107-11.
63. Seidenfeld J, Piper M, Flamm C, et al. 2001. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst, 93:1204-14.
64. Seidenfeld J, Piper M, Aronson N. 2002. systematic review of controlled trials on erythropoietin to support evidence-based guidelines. Oncology (Williston Park), 16(9 Suppl 10):171-88.
65. Sepandj F, Jindal K, West M, et al. 1996. Economic appraisal of maintenance parenteral iron administration in treatment of anemia in chronic haemodialysis patients. Neprol Dial Transplant, 11:319-22.
66. Siakantaris MP, Angelopoulou MK, Vassilakopoulos TP, et al. 2000. Correction of disease related anemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: maintenance is necessary to sustain response. Leuk Lymphoma, 40(1-2):141-7.
67. Steensma DP, Molina R, Sloan JA, et al. 2006. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol, 24:1079-89.
68. Straus DJ, Testa MA, Sarokhan BJ, et al. 2006. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer, 107:1909-17.
69. Thomas C, Kirschbaum A, Boehm D, et al. 2006. The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy. Med Oncol, 23:23-36.
70. Tonelli M, Blake PG, Muirhead N, et al. 2001. Predictors of erythropoietin responsiveness in chronic hemodialysis patients. Asaio J, 47:82-5.
71. Van Belle S, Paridaens R, Evers O, et al. 2005. Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool. Support Care Cancer, 13:246-54.
72. Vansteenkiste J. Wauters I. 2005. The use of darbepoetin alfa for the treatment of chemotherapy-induced anemia. Expert Opin Pharmacother, 6:429-40.
73. Witzig TE, Silberstein PT, Loprinzi CL, et al. 2005. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol, 23:2606-17.
74. Yellen SB, Cella DF, Webster K, et al. 1997. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage, 13:63-74.